Justin Gatwood1,2, Marie Chisholm-Burns3, Robert Davis4, Fridtjof Thomas5, Praveen Potukuchi6, Adriana Hung7,8, Csaba P Kovesdy6,9. 1. University of Tennessee Health Science Center, College of Pharmacy, Memphis, TN, USA. jgatwood@uthsc.edu. 2. Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, 301 S. Perimeter Park Drive, Suite 220, Nashville, TN, 37211, USA. jgatwood@uthsc.edu. 3. University of Tennessee Health Science Center, College of Pharmacy, Memphis, TN, USA. 4. University of Tennessee Health Science Center, Center for Biomedical Informatics, Memphis, TN, USA. 5. University of Tennessee Health Science Center, Department of Preventive Medicine, Memphis, TN, USA. 6. Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA. 7. Vanderbilt University School of Medicine, Nashville, TN, USA. 8. VA Tennessee Valley Healthcare System, Nashville, TN, USA. 9. Memphis VA Medical Center, Memphis, TN, USA.
Abstract
BACKGROUND: Adherence to prescribed medications is connected with, but is not a guarantee of, improved disease management and health outcomes. It remains unclear whether underlying health disparities exist among patients adherent to therapy and whether differences in outcomes vary by race and residential areas of the country. OBJECTIVE: To determine the extent of racial and regional variation in outcomes within 5 years of oral antidiabetic drug initiation among veterans adherent to therapy. DESIGN: Retrospective cohort study of 83,265 US Veterans Health Administration data, 2002-2014 PATIENTS: US veterans with uncomplicated diabetes and taking oral antidiabetic agents MAIN MEASURES: Veterans initially adherent to oral antidiabetic therapy were followed for up to 5 years, and comparisons focused on differences between non-Hispanic White and non-Hispanic Black veterans across geographic region and residential type (urban or rural). Outcomes included composite cardiovascular events, composite cerebrovascular events, or all-cause mortality using Poisson and adjusted Cox proportional hazards models. KEY RESULTS: Cardiovascular event and all-cause mortality rates differed by race and region, while urban/rural differences were evident for cerebrovascular events and all-cause mortality. For non-Hispanic Blacks, the mortality rate was half that compared to non-Hispanic Whites (6.5 [95% CI 5.8-7.2] versus 13.3 [95% CI 12.9-13.8], p < 0.0001). Compared to the Northeast, all other regions had higher adjusted hazards for cardiovascular or cerebrovascular events (with a single exception), but no regional differences in all-cause mortality were observed. Models with interactions demonstrated that racial differences in cardiovascular events and all-cause mortality were isolated to the Midwest (HR 1.99 [95% CI 1.301-3.06; HR 1.64 [95% CI 1.210-2.215]) and South (HR 1.69 [85% CI 1.347-2.131]; HR 1.27 [95% CI 1.095-1.470]). CONCLUSIONS: Despite adherence to therapy, differences in outcomes are likely among veterans with diabetes based on race and geography. Localized analyses may uncover specific social determinants contributing to differences in outcomes.
BACKGROUND: Adherence to prescribed medications is connected with, but is not a guarantee of, improved disease management and health outcomes. It remains unclear whether underlying health disparities exist among patients adherent to therapy and whether differences in outcomes vary by race and residential areas of the country. OBJECTIVE: To determine the extent of racial and regional variation in outcomes within 5 years of oral antidiabetic drug initiation among veterans adherent to therapy. DESIGN: Retrospective cohort study of 83,265 US Veterans Health Administration data, 2002-2014 PATIENTS: US veterans with uncomplicated diabetes and taking oral antidiabetic agents MAIN MEASURES: Veterans initially adherent to oral antidiabetic therapy were followed for up to 5 years, and comparisons focused on differences between non-Hispanic White and non-Hispanic Black veterans across geographic region and residential type (urban or rural). Outcomes included composite cardiovascular events, composite cerebrovascular events, or all-cause mortality using Poisson and adjusted Cox proportional hazards models. KEY RESULTS: Cardiovascular event and all-cause mortality rates differed by race and region, while urban/rural differences were evident for cerebrovascular events and all-cause mortality. For non-Hispanic Blacks, the mortality rate was half that compared to non-Hispanic Whites (6.5 [95% CI 5.8-7.2] versus 13.3 [95% CI 12.9-13.8], p < 0.0001). Compared to the Northeast, all other regions had higher adjusted hazards for cardiovascular or cerebrovascular events (with a single exception), but no regional differences in all-cause mortality were observed. Models with interactions demonstrated that racial differences in cardiovascular events and all-cause mortality were isolated to the Midwest (HR 1.99 [95% CI 1.301-3.06; HR 1.64 [95% CI 1.210-2.215]) and South (HR 1.69 [85% CI 1.347-2.131]; HR 1.27 [95% CI 1.095-1.470]). CONCLUSIONS: Despite adherence to therapy, differences in outcomes are likely among veterans with diabetes based on race and geography. Localized analyses may uncover specific social determinants contributing to differences in outcomes.
Authors: Manel Pladevall; L Keoki Williams; Lisa Ann Potts; George Divine; Hugo Xi; Jennifer Elston Lafata Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Csaba P Kovesdy; Keith C Norris; L Ebony Boulware; Jun L Lu; Jennie Z Ma; Elani Streja; Miklos Z Molnar; Kamyar Kalantar-Zadeh Journal: Circulation Date: 2015-09-18 Impact factor: 29.690
Authors: Michael K Chapko; Steven J Borowsky; John C Fortney; Ashley N Hedeen; Marsha Hoegle; Matthew L Maciejewski; Carol VanDeusen Lukas Journal: Med Care Date: 2002-07 Impact factor: 2.983
Authors: Alyce S Adams; Connie Mah Trinacty; Fang Zhang; Ken Kleinman; Richard W Grant; James B Meigs; Stephen B Soumerai; Dennis Ross-Degnan Journal: Diabetes Care Date: 2008-01-30 Impact factor: 19.112
Authors: Kimberley Krapek; Kathleen King; Susan S Warren; Karen G George; Dorothy A Caputo; Karen Mihelich; Elizabeth M Holst; Michael B Nichol; Sheng G Shi; Kevin B Livengood; Steve Walden; Teresa J Lubowski Journal: Ann Pharmacother Date: 2004-07-06 Impact factor: 3.154